Nevotek

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nevotek

What is Nevotek? (Identity and General Purpose)

Property Description
Active ingredient Levofloxacin
Form Tablet, Solution for infusion, Ophthalmic solution
Pharmacological class Fluoroquinolone Antibiotic (Third Generation)
Common use (General) Clearing systemic and localized bacterial infections
Origin Synthetic (L-isomer of Ofloxacin)

What Type of Medicine is Nevotek? (Definition and Classification)

Nevotek is a synthetic antibacterial agent containing the active substance Levofloxacin, which is a broad-spectrum medicine used to treat bacterial infections. This medicine belongs to the fluoroquinolone class of antibiotics and is recognized as a third-generation derivative. Pharmacological studies support the classification of Levofloxacin as having enhanced activity against certain Gram-positive organisms, such as Streptococcus pneumoniae, compared to earlier agents.

The product is chemically produced as the purified L-isomer of the older compound Ofloxacin, which is a key differentiation factor that yields its targeted efficacy and enhanced potency.

Composition, Origin, and Available Forms (Component Analysis)

The composition of Nevotek is centered on the single active ingredient, Levofloxacin. It is synthetic in origin and is available for multiple methods of delivery, primarily as oral tablets and as a solution for intravenous infusion for systemic delivery. The availability of these forms ensures the medicine can be effectively administered, whether rapid systemic distribution is required via the intravenous solution or a convenient option for continuing treatment is needed via the oral tablets.

The General Purpose of This Antibacterial Agent (High-Level Function)

The overall general function of Nevotek is to serve as a potent bactericidal agent that actively eliminates the bacterial source of an infection. It achieves this fundamental benefit through its bactericidal action, which works by selectively interfering with the two critical bacterial enzymes, DNA gyrase and topoisomerase IV. This mechanism ensures the swift and effective eradication of the susceptible bacterial population fueling the illness, helping the body overcome systemic and localized bacterial illnesses.

Regulatory References

  1. Levofloxacin - StatPearls - NCBI Bookshelf
  2. Levofloxacin - WHO Electronic Essential Medicines List

What side effects are possible with Nevotek?

Official Adverse Reactions and Safety Profile

The safety profile of Nevotek (Levofloxacin) is structured by government health authorities to classify potential effects by incidence and the body system affected. Adverse reactions are grouped into categories such as Common, Uncommon, and Rare, based on documented frequency in regulatory sources.

Commonly Documented Adverse Reactions

Side effects frequently reported in official labeling include reactions affecting the Gastrointestinal and Nervous Systems, such as nausea, diarrhea, headache, and insomnia. Reactions are categorized across various System-Organ Classes (SOCs), which also include Musculoskeletal and Connective Tissue Disorders.

Serious Adverse Reactions and Warnings

Specific serious adverse reactions are subject to mandatory regulatory warnings due to their clinical significance:

  • Tendinopathy and Tendon Rupture: Inflammation and tearing of tendons, particularly the Achilles tendon, can occur during treatment or for up to several months after discontinuation.
  • Peripheral Neuropathy: Nerve damage that may be disabling and potentially irreversible, with symptoms that can begin rapidly after starting treatment.
  • Cardiovascular Risks: Warnings include the risk of QT interval prolongation and reports of Aortic Aneurysm or Dissection.
  • Hepatotoxicity (severe liver injury) and Clostridioides difficile-Associated Diarrhoea are also documented as serious risks.

Population-Specific Safety Considerations

The risk of tendon disorders and aortic events is documented as being increased in Older Adults (generally over 60 years of age). Due to concerns about joint toxicity, use in the Paediatric Population is generally restricted in many jurisdictions. Furthermore, caution is noted for patients with Renal Impairment due to the potential for increased drug exposure.

This framework, established by regulatory documents, provides a clear, categorized summary of the known risks associated with the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Nevotek (Levofloxacin) describes specific manifestations and required actions in the event of an overdose. Immediate medical attention is mandatory if an excessive amount is taken or suspected.

Documented Overdose Manifestations

System Affected Observed Clinical Signs (As stated in Label)
Central Nervous System (CNS) Convulsive seizures, impaired consciousness, confusion, tremor, dizziness, and hallucinations.
Cardiovascular Prolongation of the QT interval, creating a risk for the life-threatening arrhythmia Torsade de Pointes. Tachycardia may also occur.
Gastrointestinal Nausea and mucosal erosions have been reported following acute exposure.

Emergency Actions and Management

Regulatory guidance explicitly states that no specific antidote exists for an overdose of this medication. Treatment is limited to symptomatic and supportive measures. Due to the documented cardiac risks, continuous ECG monitoring is required for observation. Gastric lavage may be performed after acute oral ingestion. Patients with existing renal impairment may require special consideration due to reduced drug clearance. Urgent medical evaluation is required to manage potential severe outcomes, particularly seizures and cardiac complications.

Therapeutic Uses of Nevotek

What Nevotek treats: main uses and benefits

Nevotek is an established medication used within therapeutic regimens to address specific cardiovascular conditions. The primary therapeutic domain for Nevotek is the management of primary hypertension (high blood pressure). It is administered to support the lowering of elevated blood pressure levels, which is a component of a comprehensive strategy to promote cardiovascular wellness.

In addition to its use in hypertension, Nevotek may be considered as a supportive element of care for adult patients with stable, chronic heart failure. Its inclusion in this treatment plan is based on its capacity to contribute to the overall management of the condition when used alongside other prescribed treatments.

The clinical purpose of treatment with Nevotek is to provide support for a favorable therapeutic effect on the target conditions. It is an agent intended to be part of a defined treatment plan guided by a healthcare professional. Approved therapeutic applications and indications are subject to regulatory oversight.

Eligibility and Restrictions for Use

Official Eligibility Rules for Nevotek (Levofloxacin)

Nevotek is strictly regulated for use in specific populations as defined by health authorities. Eligibility is primarily restricted to adults (18 years of age and older). Use is prohibited or strictly limited in several groups based on regulatory mandates.

Populations Who Must Not Use Nevotek (Contraindications)

Category Regulatory Status
Age and Developmental Status Contraindicated in children, adolescents, pregnant women, and breastfeeding women.
Prior Drug Reaction Contraindicated with a history of hypersensitivity to Levofloxacin or any other quinolone antibacterial.
Comorbidity History Contraindicated for patients with a history of tendon disorders related to prior fluoroquinolone use or a history of epilepsy.

Populations Requiring Restricted or Conditional Use

Use of Nevotek requires special caution or dose adjustment in certain populations. Patients with severe renal impairment must have their dosage restricted and adjusted according to the degree of functional decline. Special caution is also required for older adults and patients with comorbidities that increase central nervous system or cardiac risk, such as Diabetes Mellitus or a known risk for QT interval prolongation.

What should I know about interactions with other medicines?

The official regulatory profile for Nevotek (Levofloxacin) is structured around managing pharmacokinetic interference and documented pharmacodynamic risks.

A significant pharmacokinetic interaction involves multivalent cations, such as antacids, Sucralfate, and mineral supplements (iron, zinc). These substances can markedly reduce the systemic absorption of Levofloxacin; therefore, oral administration of Nevotek must be separated by at least two hours before or two hours after these products to mitigate the absorption loss.

A major area of pharmacodynamic restriction involves medicines that prolong the QT interval; co-administration with these agents, including certain antiarrhythmics and antipsychotics, results in an additive effect, increasing the risk of ventricular arrhythmias. Co-administration with corticosteroids carries an elevated risk of tendon rupture, which is noted as particularly significant in elderly patients. Furthermore, concurrent use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is officially associated with an increased risk of Central Nervous System (CNS) stimulation, including convulsions.

Nevotek also modifies the exposure of other specific drugs. It can enhance the anticoagulant effect of Warfarin, necessitating close monitoring of the International Normalized Ratio (INR), and may increase the plasma concentration of Theophylline, leading to a toxicity risk. Nevotek is not documented as a clinically significant inhibitor of major CYP450 enzymes.

Mechanism of Action

Dual Mechanism to Inhibit Bacterial DNA Metabolism

Nevotek acts as an inhibitor by simultaneously targeting two essential bacterial enzymes: DNA Gyrase and Topoisomerase IV. By locking these enzymes in a complex with the bacterial DNA, the drug halts the necessary processes of DNA uncoiling and chromosome separation. This dual blockade creates an irreparable cascade of cellular damage, which leads directly to the core physiological effect: the death of susceptible bacterial cells.

Mechanistic Constraints and Bypass Resistance

The drug's mechanism leads to cellular death but is inherently limited by bacterial defense strategies that reduce the drug's access or affinity for its targets. The primary constraints are target-site mutations in the enzyme genes and active efflux pumps that expel the drug from the bacterial cell. These resistance mechanisms constrain the drug's ability to reach the necessary intracellular concentration, preventing the full activation of the inhibitory mechanism and limiting the magnitude of cellular killing.

Dosage and Administration Information

Nevotek (Levofloxacin) is used for systemic delivery via oral tablets and intravenous (IV) infusion. The medicine is also available as an ophthalmic solution for topical use. One approach to its systemic administration is sequential therapy, where IV infusion may be initiated in acute settings and then transitioned to oral tablets once the patient's condition improves. The same once-daily dose is typically maintained across this transition due to the equivalent systemic absorption of both forms.

The standard adult systemic dose is administered once every 24 hours. The dose ranges from 250 mg to 750 mg per administration, depending on the course of therapy. Treatment duration is variable, ranging from brief courses of 3 to 5 days for certain uncomplicated infections to extended courses of up to 14 days or longer for complex conditions. Oral tablets may be taken without regard to food.

Specific constraints apply to IV administration: the solution is given as a slow infusion. A 500 mg dose requires a minimum infusion time of 60 minutes, while a 750 mg dose is infused over at least 90 minutes. A procedural rule involves dosage adjustment for adult patients with creatinine clearance < 50 mL/min, which dictates a reduced strength or an extended interval between doses. No dosage adjustment is generally required for patients with impaired liver function.

Recent Clinical Evidence

Nevotek: Overview of Research Evidence

Evidence for Systemic and Localized Infections

The clinical evaluation of Nevotek, which contains Levofloxacin, primarily involves Randomized Controlled Trials (RCTs) and systematic reviews. For indications such as Community-Acquired Pneumonia (CAP), research was applied in studies assessing short-term symptom patterns, focusing on outcomes like the resolution of clinical signs and microbiological outcomes. This evidence contributes to understanding the patterns observed in acute infection types.

Similarly, clinical trials have examined Nevotek in populations with complicated urinary tract infections (cUTI) and acute pyelonephritis. These studies explored the clearance of specific types of bacteria and monitored outcomes linked to inflammatory states. Research also describes the measured clinical and microbiological outcomes observed in specific patient groups, including those studied in longer-duration trials for chronic bacterial prostatitis.

Research Gaps and Special Populations

Research has explored Nevotek’s effects in distinct patient groups, including older adults (geriatric populations). However, data for certain groups, such as specific pediatric subgroups, remain insufficient. This review highlights key limitations documented in the scientific literature: follow-up durations were often limited in several studies, meaning long-term effects are not fully established. Furthermore, the applicability of research findings is constantly examined regarding widespread bacterial resistance, which introduces scientific uncertainty into the evidence base.

Key Studies & References

  1. Levofloxacin - FDA Drug Approval and Indication Information (StatPearls)
  2. Effectiveness and safety of levofloxacin in the treatment of community-acquired pneumonia: A systematic review and meta-analysis
  3. A Study to Evaluate the Safety and Effectiveness of Levofloxacin Compared With Ciprofloxacin in Patients With Chronic Bacterial Prostatitis (ClinicalTrials.gov)

Frequently Asked Questions (FAQ)

Common questions about Nevotek (FAQ)


Q: Can Nevotek be taken long-term or only for a short time?

Official product information indicates that safety has not been established for treatment courses lasting longer than 28 days in adults or 14 days in children for most approved uses. Use of the medicine beyond these durations is only considered when the potential benefit is clearly judged to be greater than the possible risks. The total duration of therapy is determined by the prescribing healthcare provider.


Q: Do older adults typically need a different dose of Nevotek?

While dosing is determined by individual factors like kidney function, official safety warnings indicate that older patients (typically over 60) have a higher risk of serious adverse reactions. This can include problems affecting the tendons and potential effects on heart rhythm. Dosing requirements are determined based on the patient's specific health profile, including kidney function.


Q: Why does Nevotek need to be used with caution in certain people?

The official Boxed Warning advises caution due to the risk of serious, disabling, and potentially irreversible side effects, which may affect tendons, nerves, and the central nervous system. Certain groups, such as those over 60, those taking corticosteroids, or individuals with pre-existing nerve or heart conditions, are listed as having an increased risk.


Q: Is there a maximum time a person can be on Nevotek?

According to regulatory documents, the safety of Nevotek has not been established for courses longer than 28 days in adults or 14 days in children for most uses. If a longer course of treatment is required, regulatory guidance indicates this must be based on a specific risk-benefit assessment.


Q: What is Nevotek actually used for?

Nevotek is a fluoroquinolone antibiotic approved to treat certain bacterial infections in adults. These uses include specific types of pneumonia, sinusitis, skin infections, and infections of the urinary tract. Official indications also include specific serious conditions like post-exposure inhalational anthrax and plague.


Q: Is Nevotek the same kind of medicine as [similar common drug name]?

The official classification for Nevotek is a fluoroquinolone antibiotic. This places it in the same class as other medicines that treat bacterial infections by interfering with bacterial DNA. Regulatory bodies often reserve this class for patients who have no alternative treatment options for certain uses.


Q: What happens if I stop taking Nevotek suddenly?

Official guidance advises against stopping the medication early, even if symptoms begin to improve. Discontinuing treatment before the prescribed duration is complete may allow some bacteria to survive and increase the risk of developing antibiotic resistance.


Q: Are there any common side effects people report online for Nevotek?

Regulatory documents list several common side effects that have been reported. These often include gastrointestinal effects like nausea, diarrhea, or constipation, as well as headache, dizziness, and trouble sleeping.


Q: I heard Nevotek causes [vague side effect]; is that true?

Official safety warnings highlight serious adverse effects that may occur. These include potentially disabling and irreversible effects on the nerves (peripheral neuropathy), the central nervous system, and a risk of problems with tendons, such as tendinitis or rupture.


Q: Can Nevotek affect my sleep pattern?

Yes, trouble sleeping, which is medically referred to as insomnia or a sleep disorder, is listed in official product information as a common or reported adverse reaction.


Q: Is it okay to take Nevotek with a common multivitamin?

Certain components found in some multivitamins, such as calcium, magnesium, and iron, can interfere with how Nevotek is absorbed in the body. Official instructions state that products containing these metal ions should be separated from the medicine by at least two hours to ensure proper effectiveness.


Q: What other medicines should not be used at the same time as Nevotek?

Official warnings detail potential interactions with several different types of medicines. These include antacids and sucralfate, as well as drugs that are known to prolong the QT interval, which relates to heart rhythm.


Q: Can women who are pregnant or breastfeeding use Nevotek?

Official information states that use during pregnancy is advised only when the potential benefit to the mother is determined to outweigh the potential risk. Regulatory information indicates that a decision must be made regarding continuing the medication or discontinuing breastfeeding.


Q: Why would someone be told they cannot use Nevotek?

Regulatory documents list contraindications, which are specific conditions that prohibit the use of the drug. These include a known history of an allergic reaction or hypersensitivity to Nevotek or other medicines in the quinolone class. It is also contraindicated in patients who have a history of epilepsy.


Q: What is the difference between Nevotek and a generic version of the drug?

The official definition of a generic version is that it is bioequivalent to the original Nevotek product. This means that regulatory bodies have determined that the generic formulation works in the body in the same way and at the same rate as the original branded medicine.


Q: Why do doctors prescribe Nevotek instead of other options?

Regulatory limitations-of-use recommend reserving Nevotek for patients who do not have alternative treatment options for certain specified infections. This guidance is in place to minimize the risk of serious side effects and the development of antibiotic resistance.


Q: How long does Nevotek stay in your system?

The rate at which the body clears the medicine is described by its mean terminal plasma elimination half-life, which is approximately 7.5 hours. This scientific measure describes the rate of clearance from the body.


Q: Are there any foods or drinks that interact with Nevotek?

The tablet form of Nevotek can generally be taken without regard to food. However, for the oral solution formulation, official instructions advise taking it on an empty stomach to ensure proper absorption.


Q: What does 'Nevotek treats [condition]' really mean in simple terms?

Nevotek is a medicine that works by killing susceptible bacteria, which is the underlying cause of the infection. It does this by interfering with the bacteria's essential DNA processes, causing the cells to die. It is important to note that, like all antibiotics, it is not effective against viral infections like a cold or the flu.


Q: Is it normal to feel [mild, vague symptom] when starting Nevotek?

It is known from regulatory data that common adverse reactions can occur when first starting the medicine. These often include general symptoms such as nausea, headache, and dizziness.


Q: Are there any studies about Nevotek use in children or teenagers?

Official information indicates that use in pediatric patients is limited to specific, serious infections like inhalational anthrax and plague in children 6 months and older. Due to a risk of musculoskeletal disorders, use is typically restricted when safer alternative treatments are available. Safety has not been established in children younger than six months.


Q: Does Nevotek have a Black Box Warning?

Yes, official product labeling carries an FDA Boxed Warning. This is the highest-level safety alert and advises patients and healthcare providers about the risk of serious, disabling, and potentially irreversible adverse reactions.


Q: What is the most serious potential side effect of Nevotek, as listed by the FDA?

The Boxed Warning highlights that the most serious potential side effects involve the tendons (tendinitis or rupture), peripheral nerves (nerve damage, or peripheral neuropathy), and the central nervous system. These adverse reactions are classified as disabling and potentially irreversible.


Q: Is Nevotek addictive?

Nevotek is an antibiotic and is not classified as a controlled substance by regulatory authorities. This means that the drug has not been found to have the potential for dependence or abuse that would require scheduling.


Q: Can I take Nevotek if I have a history of heart problems?

Caution is advised for patients who have existing heart conditions or risk factors for a heart rhythm issue known as QT interval prolongation. Patients with a very slow heart rate or low levels of potassium in the blood also require careful consideration.


Q: Can Nevotek cause problems with driving or operating machinery?

According to the Patient Medication Guide, Nevotek can cause dizziness, lightheadedness, and other central nervous system effects. Official guidance indicates that operating heavy machinery or driving should be avoided until an individual understands how the medicine affects them.


Q: What if I experience a rare or unexpected side effect from Nevotek?

The Patient Medication Guide describes that for severe symptoms, such as sudden joint pain, numbness, or tingling, the medicine should be discontinued immediately. This is necessary to prevent potential further progression of the reaction.


Q: Do you need lab tests or monitoring while taking Nevotek?

Monitoring is advised for musculoskeletal adverse events, especially when treating children. Additionally, patients with diabetes may require closer monitoring of their blood sugar levels due to the risk of fluctuations associated with this class of medicine.


Q: Is Nevotek a prescription-only medicine?

Yes, Nevotek is classified by regulatory agencies as a prescription-only medicine. It is not available over the counter.


Q: What are common patient misunderstandings about Nevotek?

A common misunderstanding that regulatory limitations address is the belief that antibiotics like Nevotek can treat viral infections. The medicine is only effective against susceptible bacteria and should not be used for common colds, flu, or other infections caused by viruses.


Q: How long after stopping Nevotek can I take other medicines that interact with it?

The clearance of the drug from the body is determined by its half-life, which is approximately 7.5 hours. This scientific information is used by healthcare providers when considering the appropriate interval (washout period) before starting other medicines that may interact.


Q: What happens if I miss a dose of Nevotek?

The official Patient Medication Guide provides information on how to handle a missed dose, stating that it should be taken as soon as it is remembered. The guidance also advises against taking more than one dose in a single 24-hour period.


Q: What kind of lifestyle factors can affect how well Nevotek works?

Official patient information includes advice on certain lifestyle factors. For example, the drug can increase sensitivity to the sun, so avoiding sun exposure and tanning beds is advised. Patients are also advised to ensure they drink plenty of fluids to assist kidney function.


Q: Why is Nevotek sometimes prescribed in combination with other medicines?

Regulatory documents indicate that Nevotek is explicitly approved for use in combination with other medicines for certain serious conditions. These include post-exposure prophylaxis for inhalational anthrax and as part of a treatment regimen for tuberculosis.

How should Nevotek be stored and disposed of?

The storage and disposal of Nevotek, whose active ingredient is Levofloxacin, must strictly adhere to regulatory labeling requirements to maintain stability.

Storage Conditions

Nevotek tablets and oral solution must be stored at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Storage instructions strictly mandate to Avoid Freezing all formulations and to Avoid Excessive Heat.

The solution for infusion requires protection from light and may also be stored in a refrigerator, 2 C to 8 C (36 F to 46 F). The infusion solution must be visually inspected for particulate matter before use.

Handling and Disposal

All medicines must be kept out of the sight and reach of children to prevent accidental exposure. Disposal of all unused product and waste residue must be carried out in accordance with all applicable Federal, State, and Local regulations. For the injectable solution, drain disposal is not recommended.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nevotek found in:

A-Z Index: